

Attorney Docket No.: LD0250 (NP)
Inventors: Salvati et al.
Serial No.: 09/885,827
Filing Date: June 20, 2001
Page 2

1-24 have been subjected to a Restriction Requirement as follows:

Group I, claims 1-7 and 9, drawn to a method for inhibiting growth of hormone-dependent tumor cells, classified in class 514, subclass 2;

Group II, claims 8 and 24, drawn to a selective androgen receptor modulator and a pharmaceutical composition, classified in classes 536 and 514, subclasses 24.5 and 1, respectively;

Group III, claims 10-11, drawn to a method of identifying a selective androgen receptor modulator, classified in class 435, subclass 7.23;

Group IV, claims 12-16 and 20-21, drawn to a molecule or molecular complex, classified in class 702, subclass 27;

Group V, drawn to a machine-readable storage medium, classified in class 211, subclass 41.12; and

Group VI, drawn to a computational method of designing an androgen receptor synthetic ligand, classified in class 702, subclass 19.

The Examiner suggests that Groups I, II and III, Groups IV and VI, and Group V, are independent because they are directed to different chemical and entity types regarding the critical limitations therein.

Further, with respect to Groups I, II and III, the Examiner

Attorney Docket No.: LD0250 (NP)
Inventors: Salvati et al.
Serial No.: 09/885,827
Filing Date: June 20, 2001
Page 3

has acknowledged the relatedness as product and process of use, but suggests that they are distinct because the androgen receptor modulator for Group II can be utilized in different methods other than those of Groups I and III.

The Examiner has also acknowledged the relatedness of Groups IV and VI as product and process of use but suggests that they are distinct because the molecule or molecular complex of Group IV can be utilized in different methods other than that of Group VI.

Applicants respectfully traverse this Restriction Requirement.

MPEP §803 provides two criteria which must be met for a restriction requirement to be proper. The first is that the inventions be independent or distinct. The second is that there would be a serious burden on the Examiner if the restriction is not required. A proper search of the prior art relating to the selective androgen receptor modulators of Group II should also reveal any prior art relating to the methods for use as set forth in Group I, as well as methods and means for identification and design of such modulators as set forth in Groups III-VI. Thus, it does not appear that a serious burden would be placed upon the Examiner if restriction were not made.


Attorney Docket No.: LD0250 (NP)
Inventors: Salvati et al.
Serial No.: 09/885,827
Filing Date: June 20, 2001
Page 4

Accordingly, since this Restriction Requirement does not meet both criteria as set forth in MPEP § 803 to be proper, it is respectfully requested that this Restriction Requirement be withdrawn.

However, in an earnest effort to be completely responsive, Applicants elect Group I, claims 1-7 and 9 with traverse.

Applicants believe that the foregoing comprises a full and complete response to the Office Action of record.

Respectfully submitted,



Kathleen A. Tyrrell

Reg. No. 38,350

Date: December 9, 2002

LICATA & TYRRELL P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515